Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0893. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR known ✓ | P47871 | 20/20 | 1.00 |
| ▸ | GIPR | P48546 | 13/20 | 1.00 |
| ▸ | VIPR2 | P41587 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | VIPR1 | P32241 | 1/20 | 1.00 |
| ▸ | DUSP2 | Q05923 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 2/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0893 SCHEMBL29363684 | 1.00 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL2355321 | 1.00 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL13644751 | 0.94 | GCGR (0.88) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667874 | 0.92 | GCGR (0.84) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667510 | 0.92 | GCGR (0.84) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667512 | 0.91 | GCGR (0.83) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3251729 | 0.91 | GCGR (0.83) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL825813 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL1966239 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL827984 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | claimed |
| US-20220125762-A1 | SMALL MOLECULE ANTAGONIST TO PACAP RECEPTOR AND USES THEREOF | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3177614-B1 | FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3177287-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | MERCK SHARP & DOHME CORP. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | MERCK SHARP & DOHME CORP. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3383388-B1 | ARYL ACYLSULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20090054662-A1 | Process for synthesizing a substituted pyrazole | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054662-A1 | Process for synthesizing a substituted pyrazole | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007015999-A2 | PROCESS FOR SYNTHESIZING A SUBSTITUTED PYRAZOLE | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2005121097-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | GCGR 188/4885GIPR 205/4885VIPR2 1017/4885 |
| US-20090054662-A1 | Process for synthesizing a substituted pyrazole | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 33/4885 |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 98/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 40/4885 |
| US-20220125762-A1 | SMALL MOLECULE ANTAGONIST TO PACAP RECEPTOR AND USES THEREOF | OPRK1, OPRL1, OPRM1 | GCGR 295/4885GIPR 192/4885VIPR2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.